First Scientific Symposium Translational Research in Alzheimer. Paris - September 18, 2009 Collège de France

Transcription

1 First Scientific Symposium Translational Research in Alzheimer Paris - September 18, 2009 Collège de France 8h30 Welcome coffee 9h-9h30 Opening remarks - Philippe Lagayette, President of French National Foundation on Alzheimer's disease and related disorders - Florence Lustman, Vice-President of French National Foundation on Alzheimer's disease and related disorders - Christian Lajoux, President of Leem Recherche 1

2 9h30-10h 30 Round table 1: Physiopathological mechanisms: old and new targets 9h30-10h: Pr Joël Ménard (President of the Scientific Board, French National Foundation on Alzheimer's disease and related disorders) Dr Jesus Benavides (Global Head, Neurological Diseases Drug Discovery, sanofi-aventis) Dr Yoichi Iimura (Senior Scientist, Eisai Tsukuba Research Lab) Discovery of Donepezil (Aricept ) Dr Fréderic Checler (Research Director Inserm, Head of the team Cellular and Molecular Biology of Normal and Pathological Cerebral Aging ) Does proteolysis contribute to the aetiology of Alzheimer's disease? Pr Luc Buée (Research Director, Head of the team «Alzheimer & Tauopathies») Tau pathology, epiphenomenon or key actor? Dr Tim Ashwood (Disease Area Medical leader, Neurology and Cognition Senior Principal, AstraZeneca) Development of an alpha4 beta2 neuronal nicotinic receptor agonist for the symptomatic treatment of Alzheimer s disease 10h - 10h30: Round table discussion, with Pr Joël Ménard 10h30 11h Coffee break 11h 12h30 Round Table 1 (second part) 11h 11h30 Pr Joël Ménard (President of the Scientific Board, French National Foundation on Alzheimer's disease and related disorders) Dr Jesus Benavides (Global Head, Neurological Diseases Drug Discovery, sanofi-aventis) Dr Ana Graf (Global Program Medical Director CAD106, Novartis Pharma AG) Active abeta immunotherapy: from transgenic mice to patients Dr Eric Siemers 2

3 (Medical Director, Alzheimer's Disease Team, Lilly) Evolving evidence for dynamic changes in amyloid plaques in humans Dr Philippe Hantraye (Director of the Molecular imaging research center (MIRCen), CEA, France) PET Imaging and high fields MRI, NMR Spectroscopy, translational markers 11h30 12h: Round table discussion with Pr Joël Ménard 12h 12h30: General discussion 12h30-13h30 LUNCH on site 3

4 13h30-15h45 Round Table 2: Clinical trials at the prodromal stage of the disease 13h30 : Dr Emmanuel Canet (R&D President, Servier) Pr Cristina Sampaio (Member of Committee for Medicinal Products for Human Use, EMEA) Pr Bruno Dubois (Professor of Medicine, Head of the Inserm U610, Head of Cognitive & Behavioural diseases Center, Hospital Pitié-Salpêtrière, Paris) A new concept for Alzheimer s disease Dr Marie-José Hoellinger (Global Program Head, Novartis) Conducting clinical trials in patients at early stages of Alzheimer s disease: challenges and opportunities Pr Jean-Marc Orgogozo (Head of Clinical Neurosciences Pole CHU & University of Bordeaux) New design for new concept 14h 14h30: Round table discussion with Pr Cristina Sampaio Dr George Garibaldi (Global Head CNS Clinical Development, Roche) Drug development in Alzheimer's Prodrome, a drug development perspective Dr Barbara Putz (Head Global Clinical Development Molecular, Bayer) Imaging ß-amyloid in the brain as possible tool to enrich the patient population in clinical pre-alzheimer trials? Dr William Zeigler Potter (Vice President Franchise Integrator Neuroscience & Ophthalmology, MSD) Progress in Understanding Peptides in Cerebrospinal Fluid: From Abeta to Proteomics 14h45 15h15: Round table discussion with Pr Cristina Sampaio 15h15 15h45: General discussion 15h45 16h15 Coffee break 4

5 16h15 18h30 Round table 3: Recruitment of patients in clinical trials 16h15: Dr Eric Abadie (Chairman of Committee for Medicinal Products for Human Use, EMEA) Hélène Mathiex Fortunet (Medical Director, Ipsen) Dr Jean-Charles Lambert (Research Director Inserm, Inserm U744) Genetic biomarkers Dr Rachel Schindler (Executive Director, Development Team Leader, Pfizer) Issues and Challenges in the Conduct of Global Clinical Trials in Alzheimer's Disease Dr Marina Zvartau-Hind (Director, GlaxoSmithKline) GSK experience in recruitment into Alzheimer's disease clinical trials 16h40 17h10 : Round table discussion with Dr Eric Abadie Michèle Micas (France Alzheimer Delegate) Patients & informal caregivers point of view Pr Bruno Vellas (Professor of Medicine, Head of the Gerontopole Center, CHU de Toulouse, France) Network for cooperative Alzheimer s trials (FN-CMRR, EADC) Pr Florence Pasquier (Professor of Neurology, Head of the Research & Resources Memory Center Lille) Interest of patients with young onset dementia in pharmaceutical trials Pr Olivier Blin (Professor of Clinical Pharmacology & IMI pharmacog consortium, Marseille, France) Integrated Public Private data base analysis : a new approach in Alzheimer disease research 17h30 18h : Round table discussion with Dr Eric Abadie 18h 18h30 : General discussion 18h30 Closing remarks Dr Catherine Lassale (General Secretary of Leem Recherche) Pr Philippe Amouyel (General Director of French National Foundation on Alzheimer's disease and related disorders) 5